Willekens Barbara
Willekens Barbara
Neurologist at Antwerp University Hospital
Verified email at
Cited by
Cited by
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Ofatumumab versus teriflunomide in multiple sclerosis
SL Hauser, A Bar-Or, JA Cohen, G Comi, J Correale, PK Coyle, AH Cross, ...
New England Journal of Medicine 383 (6), 546-557, 2020
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ...
The Lancet 387 (10023), 1075-1084, 2016
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
H Butzkueven, L Kappos, H Wiendl, M Trojano, T Spelman, I Chang, ...
Journal of Neurology, Neurosurgery & Psychiatry 91 (6), 660-668, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
BAC Cree, G Cutter, JS Wolinsky, MS Freedman, G Comi, G Giovannoni, ...
The Lancet Neurology 19 (12), 988-997, 2020
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell …
B Willekens, S Presas-Rodríguez, MJ Mansilla, J Derdelinckx, WP Lee, ...
BMJ open 9 (9), e030309, 2019
Frequency and characterization of movement disorders in anti-IgLON5 disease
C Gaig, Y Compta, A Heidbreder, MJ Marti, MJ Titulaer, Y Crijnen, B Högl, ...
Neurology 97 (14), e1367-e1381, 2021
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised …
JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, ...
The Lancet Neurology 21 (7), 608-619, 2022
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial
RE Gonsette, C Sindic, MB D'hooghe, PP De Deyn, R Medaer, A Michotte, ...
Multiple Sclerosis Journal 16 (4), 455-462, 2010
Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis
D De Ridder, F Van der Aa, J Debruyne, MB D’hooghe, B Dubois, ...
Clinical neurology and neurosurgery 115 (10), 2033-2040, 2013
Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study
M D'hooghe, G Van Gassen, D Kos, O Bouquiaux, M Cambron, D Decoo, ...
Multiple Sclerosis and Related Disorders 22, 90-96, 2018
The effectiveness of a self-management occupational therapy intervention on activity performance in individuals with multiple sclerosis-related fatigue: a randomized-controlled …
D Kos, M Duportail, J Meirte, M Meeus, MB D’hooghe, G Nagels, ...
International Journal of Rehabilitation Research 39 (3), 255-262, 2016
What is in a name? Comparing diagnostic criteria for chronic fatigue syndrome with or without fibromyalgia
M Meeus, K Ickmans, F Struyf, D Kos, L Lambrecht, B Willekens, P Cras, ...
Clinical rheumatology 35, 191-203, 2016
Myoclonus and cerebellar ataxia following COVID‐19
F Dijkstra, T Van den Bossche, B Willekens, P Cras, D Crosiers
Movement disorders clinical practice 7 (8), 974, 2020
IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes
M Montagna, R Amir, I De Volder, M Lammens, J Huyskens, B Willekens
Frontiers in neurology 9, 329, 2018
Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors
K Thewissen, AH Nuyts, N Deckx, BV Wijmeersch, G Nagels, M D’hooghe, ...
Multiple sclerosis journal 20 (5), 548-557, 2014
Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial
M Cambron, J Mostert, M D’Hooghe, G Nagels, B Willekens, J Debruyne, ...
Multiple Sclerosis Journal 25 (13), 1728-1735, 2019
Beyond the magic bullet: Current progress of therapeutic vaccination in multiple sclerosis
B Willekens, N Cools
CNS drugs 32 (5), 401-410, 2018
Sativex®(nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
M D’hooghe, B Willekens, V Delvaux, M D’haeseleer, D Guillaume, ...
BMC neurology 21 (1), 227, 2021
The system can't perform the operation now. Try again later.
Articles 1–20